1,313
Views
3
CrossRef citations to date
0
Altmetric
Commentary

Know Your Enemy: Potential Role of Cabergoline to Target Neoangiogenesis in Endometriosis

, MD, PhDORCID Icon, , MDORCID Icon, , MDORCID Icon, , MDORCID Icon, , MD , PhDORCID Icon, , MDORCID Icon & , MDORCID Icon show all

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Simone Garzon, Antonio Simone Laganà, Fabio Barra, Jvan Casarin, Antonella Cromi, Ricciarda Raffaelli, Stefano Uccella, Massimo Franchi, Fabio Ghezzi & Simone Ferrero. (2021) Novel drug delivery methods for improving efficacy of endometriosis treatments. Expert Opinion on Drug Delivery 18:3, pages 355-367.
Read now
Simone Garzon, Antonio Simone Laganà, Fabio Barra, Jvan Casarin, Antonella Cromi, Ricciarda Raffaelli, Stefano Uccella, Massimo Franchi, Fabio Ghezzi & Simone Ferrero. (2020) Aromatase inhibitors for the treatment of endometriosis: a systematic review about efficacy, safety and early clinical development. Expert Opinion on Investigational Drugs 29:12, pages 1377-1388.
Read now

Articles from other publishers (1)

Yuehan Wang, Bo Li, Yang Zhou, Yizi Wang, Xue Han, Shitai Zhang, Zheng He & Ling Ouyang. (2021) Does Endometriosis Disturb Mental Health and Quality of Life? A Systematic Review and Meta-Analysis. Gynecologic and Obstetric Investigation 86:4, pages 315-335.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.